Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment.

Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, Güntert A, Kraut M, Ferrucci L, Davatzikos C, Lovestone S, Resnick SM.

Neuroimage. 2012 Jan 2;59(1):212-7. doi: 10.1016/j.neuroimage.2011.07.056.

2.

Plasma clusterin levels and the rs11136000 genotype in individuals with mild cognitive impairment and Alzheimer's disease.

Mullan GM, McEneny J, Fuchs M, McMaster C, Todd S, McGuinness B, Henry M, Passmore AP, Young IS, Johnston JA.

Curr Alzheimer Res. 2013 Nov;10(9):973-8.

PMID:
24117116
3.

Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease.

Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, Güntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S.

Arch Gen Psychiatry. 2010 Jul;67(7):739-48. doi: 10.1001/archgenpsychiatry.2010.78.

4.

Evolution of global and local grey matter atrophy on serial MRI scans during the progression from MCI to AD.

Spulber G, Niskanen E, Macdonald S, Kivipelto M, Padilla DF, Julkunen V, Hallikainen M, Vanninen R, Wahlund LO, Soininen H.

Curr Alzheimer Res. 2012 May;9(4):516-24.

PMID:
22191564
5.

Volumes of lateral temporal and parietal structures distinguish between healthy aging, mild cognitive impairment, and Alzheimer's disease.

Hänggi J, Streffer J, Jäncke L, Hock C.

J Alzheimers Dis. 2011;26(4):719-34. doi: 10.3233/JAD-2011-101260.

PMID:
21709375
6.

Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease.

Jongbloed W, van Dijk KD, Mulder SD, van de Berg WD, Blankenstein MA, van der Flier W, Veerhuis R.

J Alzheimers Dis. 2015;46(4):1103-10. doi: 10.3233/JAD-150036.

PMID:
26402636
7.

Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease.

Chiu MJ, Chen YF, Chen TF, Yang SY, Yang FP, Tseng TW, Chieh JJ, Chen JC, Tzen KY, Hua MS, Horng HE.

Hum Brain Mapp. 2014 Jul;35(7):3132-42. doi: 10.1002/hbm.22390.

PMID:
24129926
8.

MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease.

Devanand DP, Bansal R, Liu J, Hao X, Pradhaban G, Peterson BS.

Neuroimage. 2012 Apr 15;60(3):1622-9. doi: 10.1016/j.neuroimage.2012.01.075.

9.

Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease.

Mattsson N, Insel P, Tosun D, Zhang J, Jack CR Jr, Galasko D, Weiner M; Alzheimer’s Disease Neuroimaging Initiative..

PLoS One. 2013 Dec 31;8(12):e85443. doi: 10.1371/journal.pone.0085443.

10.

Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration.

Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC; Alzheimer's Disease Neuroimaging Initiative..

Neurology. 2013 Feb 12;80(7):648-54. doi: 10.1212/WNL.0b013e318281ccd3.

11.

Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease.

Yi HA, Möller C, Dieleman N, Bouwman FH, Barkhof F, Scheltens P, van der Flier WM, Vrenken H.

J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):425-32. doi: 10.1136/jnnp-2014-309105.

PMID:
25904810
12.

Association between fully automated MRI-based volumetry of different brain regions and neuropsychological test performance in patients with amnestic mild cognitive impairment and Alzheimer's disease.

Arlt S, Buchert R, Spies L, Eichenlaub M, Lehmbeck JT, Jahn H.

Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):335-44. doi: 10.1007/s00406-012-0350-7.

PMID:
22940716
13.

Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease.

Bilello M, Doshi J, Nabavizadeh SA, Toledo JB, Erus G, Xie SX, Trojanowski JQ, Han X, Davatzikos C.

J Alzheimers Dis. 2015;48(4):987-94. doi: 10.3233/JAD-150400.

14.

Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease.

Douaud G, Menke RA, Gass A, Monsch AU, Rao A, Whitcher B, Zamboni G, Matthews PM, Sollberger M, Smith S.

J Neurosci. 2013 Jan 30;33(5):2147-55. doi: 10.1523/JNEUROSCI.4437-12.2013.

15.

White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters.

Lindemer ER, Salat DH, Smith EE, Nguyen K, Fischl B, Greve DN; Alzheimer's Disease Neuroimaging Initiative..

Neurobiol Aging. 2015 Sep;36(9):2447-57. doi: 10.1016/j.neurobiolaging.2015.05.011.

16.

MRI and CSF studies in the early diagnosis of Alzheimer's disease.

de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.

J Intern Med. 2004 Sep;256(3):205-23.

17.

Mapping ventricular expansion onto cortical gray matter in older adults.

Madsen SK, Gutman BA, Joshi SH, Toga AW, Jack CR Jr, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative (ADNI)..

Neurobiol Aging. 2015 Jan;36 Suppl 1:S32-41. doi: 10.1016/j.neurobiolaging.2014.03.044.

18.

3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease.

Whitwell JL, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, Petersen RC, Jack CR Jr.

Brain. 2007 Jul;130(Pt 7):1777-86.

19.

An MRI brain atrophy and lesion index to assess the progression of structural changes in Alzheimer's disease, mild cognitive impairment, and normal aging: a follow-up study.

Zhang N, Song X, Zhang Y, Chen W, D'Arcy RC, Darvesh S, Fisk JD, Rockwood K; Alzheimer's disease Neuroimaging Initiative..

J Alzheimers Dis. 2011;26 Suppl 3:359-67. doi: 10.3233/JAD-2011-0048.

PMID:
21971475
20.

In vivo parahippocampal white matter pathology as a biomarker of disease progression to Alzheimer's disease.

Solodkin A, Chen EE, Van Hoesen GW, Heimer L, Shereen A, Kruggel F, Mastrianni J.

J Comp Neurol. 2013 Dec 15;521(18):4300-17. doi: 10.1002/cne.23418.

PMID:
23839862
Items per page

Supplemental Content

Support Center